Matthew Davis

1.3k total citations
46 papers, 987 citations indexed

About

Matthew Davis is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Immunology. According to data from OpenAlex, Matthew Davis has authored 46 papers receiving a total of 987 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Economics and Econometrics, 9 papers in Pediatrics, Perinatology and Child Health and 8 papers in Immunology. Recurrent topics in Matthew Davis's work include Health Systems, Economic Evaluations, Quality of Life (8 papers), Adolescent and Pediatric Healthcare (5 papers) and Epilepsy research and treatment (5 papers). Matthew Davis is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (8 papers), Adolescent and Pediatric Healthcare (5 papers) and Epilepsy research and treatment (5 papers). Matthew Davis collaborates with scholars based in United States, Germany and Spain. Matthew Davis's co-authors include Scott J. Johnson, Qian Bai, Yujiang Fang, Ziwen Zhu, Stephanie Cline, Ahmed M. Soliman, Howard G. Birnbaum, Scott W. Johnson, Eric S. Surrey and Michael C. Snabes and has published in prestigious journals such as Gastroenterology, Cancer Research and The American Journal of Gastroenterology.

In The Last Decade

Matthew Davis

45 papers receiving 955 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew Davis United States 17 157 144 143 137 124 46 987
Francesca Bovis Italy 21 144 0.9× 260 1.8× 24 0.2× 132 1.0× 49 0.4× 116 1.3k
Marouane Boubaya France 22 86 0.5× 117 0.8× 30 0.2× 36 0.3× 170 1.4× 69 1.4k
Jean Louis Golmard France 23 127 0.8× 61 0.4× 29 0.2× 41 0.3× 146 1.2× 47 1.8k
Alessandra Spagnoli Italy 24 108 0.7× 47 0.3× 18 0.1× 69 0.5× 60 0.5× 88 1.6k
Cornelia Schneider Switzerland 19 122 0.8× 51 0.4× 14 0.1× 33 0.2× 116 0.9× 35 1.3k
Grammati Sarri United States 14 24 0.2× 78 0.5× 47 0.3× 102 0.7× 35 0.3× 39 743
Jeng‐Yuan Chiou Taiwan 17 169 1.1× 36 0.3× 24 0.2× 47 0.3× 41 0.3× 64 823
J. W. P. F. Kardaun Netherlands 18 18 0.1× 95 0.7× 55 0.4× 40 0.3× 93 0.8× 37 1.1k
Christian A. Pineau Canada 30 902 5.7× 440 3.1× 23 0.2× 114 0.8× 67 0.5× 90 2.5k
Rachel Crowley Ireland 22 47 0.3× 83 0.6× 11 0.1× 35 0.3× 159 1.3× 92 1.8k

Countries citing papers authored by Matthew Davis

Since Specialization
Citations

This map shows the geographic impact of Matthew Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Davis more than expected).

Fields of papers citing papers by Matthew Davis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Davis. The network helps show where Matthew Davis may publish in the future.

Co-authorship network of co-authors of Matthew Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Davis. A scholar is included among the top collaborators of Matthew Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Davis. Matthew Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tada, Yayoi, Ahmed M. Soliman, Andreas Pinter, et al.. (2024). Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan. Experimental Dermatology. 33(5). e15067–e15067. 1 indexed citations
2.
Tada, Yayoi, Ahmed M. Soliman, L. Puig, et al.. (2023). Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan. Dermatology and Therapy. 14(1). 99–114. 6 indexed citations
3.
Freedland, Stephen J., Matthew Davis, Andrew J. Epstein, Bhakti Arondekar, & Jasmina Ivanova. (2023). Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims. Advances in Therapy. 40(10). 4480–4492. 4 indexed citations
4.
Pérez, Vanessa, Matthew Davis, James Li, et al.. (2023). Workplace Productivity Loss and Indirect Costs Associated With Preterm Birth in the United States. Obstetrics and Gynecology. 143(1). 23–34. 3 indexed citations
5.
Davis, Matthew, et al.. (2021). Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs. ClinicoEconomics and Outcomes Research. Volume 13. 251–261. 2 indexed citations
6.
Fendrick, A. Mark, Diana Brixner, David T. Rubin, et al.. (2021). Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit. Journal of Managed Care & Specialty Pharmacy. 27(8). 1–11. 8 indexed citations
7.
8.
9.
Davis, Matthew, et al.. (2020). Direct Medical Costs of Dementia With Lewy Bodies by Disease Complexity. Journal of the American Medical Directors Association. 21(11). 1696–1704.e5. 14 indexed citations
10.
Davis, Matthew, et al.. (2020). Impact of Formulary Restrictions on Antiepileptic Drug Dispensation Outcomes. Neurology and Therapy. 9(2). 505–519. 5 indexed citations
11.
Hawkes, Jason E., Manish Mittal, Matthew Davis, & Diana Brixner. (2019). Impact of Online Prescription Management Systems on Biologic Treatment Initiation. Advances in Therapy. 36(8). 2021–2033. 6 indexed citations
12.
Brixner, Diana, Manish Mittal, David T. Rubin, et al.. (2019). <p>Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population</p>. Patient Preference and Adherence. Volume 13. 1545–1556. 16 indexed citations
13.
Davis, Matthew, Ahmed M. Soliman, Jane Castelli‐Haley, Michael C. Snabes, & Eric S. Surrey. (2018). Reintervention Rates After Myomectomy, Endometrial Ablation, and Uterine Artery Embolization for Patients with Uterine Fibroids. Journal of Women s Health. 27(10). 1204–1214. 42 indexed citations
14.
Epstein, Andrew J., Ahmed M. Soliman, Matthew Davis, et al.. (2017). Changes in Healthcare Spending After Diagnosis of Comorbidities Among Endometriosis Patients: A Difference-in-Differences Analysis. Advances in Therapy. 34(11). 2491–2502. 8 indexed citations
15.
Frenck, Robert W., Anne Fiquet, Alejandra Gurtman, et al.. (2016). Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 34(30). 3454–3462. 21 indexed citations
16.
Krishnarajah, Girishanthy, et al.. (2016). Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance. Human Vaccines & Immunotherapeutics. 12(5). 1235–1243. 9 indexed citations
17.
Davis, Matthew, et al.. (2015). The role of IL-21 in immunity and cancer. Cancer Letters. 358(2). 107–114. 122 indexed citations
18.
19.
Ivanova, Jasmina I., et al.. (2009). The Cost of Disability and Medically Related Absenteeism Among Employees with Multiple Sclerosis in the US. PharmacoEconomics. 27(8). 681–691. 61 indexed citations
20.
Davis, Matthew. (2005). The Bel Family and their Renaissance Tall-houses. 16(1). 1–13. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesca Bovis Breakdown of academic impact, for papers by Marouane Boubaya Breakdown of academic impact, for papers by Jean Louis Golmard Breakdown of academic impact, for papers by Alessandra Spagnoli Breakdown of academic impact, for papers by Cornelia Schneider Breakdown of academic impact, for papers by Grammati Sarri Breakdown of academic impact, for papers by Jeng‐Yuan Chiou Breakdown of academic impact, for papers by J. W. P. F. Kardaun Breakdown of academic impact, for papers by Christian A. Pineau Breakdown of academic impact, for papers by Rachel Crowley
Rankless by CCL
2026